Evaluation of Neoadjuvant Therapy Efficacy and Postoperative Pathological Indicators in Esophageal Cancer Using CT and Multimodal MRI

NCT06833775 | Not Yet Recruiting

• 1 other identifier: 2024-621
• Study Type: observational
• Target: 400
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study aims to predict the efficacy of different types of neoadjuvant therapy and related postoperative pathological indicators in patients with esophageal cancer based on imaging parameters from CT and multimodal MRI, as well as clinical indicators collected before and after neoadjuvant treatment.

Conditions

Esophageal Cancer; Neoadjuvant Therapy

Outcome Measures

Primary Outcomes (1)

• CT and multimodal MRI in prediction of neoadjuvant therapy efficacy and postoperative pathological indicators in esophageal cancer

  To evaluate the effectiveness of CT and multimodal MRI in determining the neoadjuvant therapy efficacy and postoperative pathological indicators in esophageal cancer.

  March 2025 - January 2030

Study Arms (2)

the group of patients who achieved pathological complete response (pCR) following neoadjuvant

the group of patients who did not achieve pCR following neoadjuvant therapy and surgery for esophage

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients were diagnosed with esophageal cancer by pathology at Zhengzhou University Affiliated Cancer Hospital from January 1, 2017 to December 31, 2024. Based on pre-treatment examinations such as endoscopic ultrasound, CT, MRI, and multidisciplinary consultation opinions, these patients underwent radical esophagectomy after receiving different kinds of neoadjuvant therapy.

You may qualify if:

• Consecutive patients with histopathological diagnosis of esophageal cancer.
• Patients underwent neoadjuvant therapy before radical surgery for esophageal cancer: neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, neoadjuvant chemotherapy plus immunotherapy, neoadjuvant chemoradiotherapy plus immunotherapy.
• All patients underwent CT and multimodal MRI examinations before and after neoadjuvant therapy.
• The preoperative clinical data and postoperative pathological data are complete.

You may not qualify if:

• Patients with other primary malignant tumors or previous anti-tumor treatment.
• CT and MRI images with poor quality.

Sponsors & Collaborators

• Henan Cancer Hospital: lead

MeSH Terms

Conditions

Esophageal Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Head and Neck Neoplasms; Digestive System Diseases; Esophageal Diseases; Gastrointestinal Diseases

Central Study Contacts

Jinrong Qu

CONTACT

(86) 0371-65587595; qjryq@126.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Professor

Study Record Dates

• First Submitted: February 13, 2025
• First Posted: February 19, 2025
• Study Start: March 1, 2025
• Primary Completion (Estimated): January 1, 2030
• Study Completion (Estimated): December 1, 2030
• Last Updated: February 20, 2025

Record last verified: 2025-02